If you are unable to view this newsletter, Please click here
Veticaltalk Pharma -  e-Newsletter

Social Media

and the

Pharma Industry

May, 2011 www.pharmafocusasia.com | Archives | Advertise

Social Media and the Pharma Industry


Every other industry is getting on the social media bandwagon. But could social media actually prove beneficial to the world of pharma?
Outside of the pharmaceutical industry, business is continually finding innovative ways to make use of social media to engage with customers in order to drive sales, maintain relationships and uncover issues. Within the world of pharma, however, an intense regulatory environment and over-protectiveness of intellectual property have proven a minefield for pharma companies keen to dip their toes into the social media pool.


White Papers
..........................................................
media pack
..........................................................
Editorial Calender
..........................................................
News
AstraZeneca and Heptares Collaborate to Investigate Important GPCR Drug Targets
May 31st, 2011
Alderley Park and Welwyn Garden City, England
AstraZeneca (NYSE: AZN) and Heptares Therapeutics today announced they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors (GPCRs). GPCRs are among the largest and most important family of proteins found in the human body, yet they become highly unstable when removed from their natural membrane-bound environments.This instability has prevented pharmaceutical researchers from understanding GPCR structures and hampered efforts to design medicines that work on GPCR targets.
Press Releases
Affymax and Takeda Announce the Submission of a New Drug Application for Peginesatide for the Treatment of Anemia Associated with Chronic Renal Failure in Patients on Dialysis
May 31st, 2011
Palo Alto, California & Osaka, Japan
Affymax, Inc. and Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational agent peginesatide (formerly known as Hematide™) for the treatment of anemia associated with chronic renal failure (CRF) in adult patients on dialysis. Peginesatide is a synthetic, PEGylated peptidic compound that binds to and activates the erythropoietin receptor and thus acts as an erythropoiesis stimulating agent (ESA).
Events
Pharma Manufacturing Summit 2011
7th - 9th, June 2011
The Fairmont Le Montreux Palace, Switzerland
The Next Generation Pharmaceutical Summit 2011 will serve as an arena for senior level executives to engage in clear and focused dialogue with their peers and examine their management objectives in a relaxed and vibrant environment.
Current Issue
Upcoming Issue

FREE! Access to the E-book
for 1 week

email us to get access details
info@pharmafocusasia.com

You are receiving this email because you are either a registered member or requested for a newsletter from Pharma Focus Asia.
To Subscribe
Subscribe for Article
To Un Subscribe from our mailing list, kindly send us a mail with the subject "unsubscribe".
Questions: For questions or assistance, please contact our Customer Support Staff : info@pharmafocusasia.com
Privacy: View our Privacy Policy
Copyright © 2010 Ochre Media Limited. All rights reserved.

Send this newsletter to a friend or colleague.
 
Your Name
Friends Name
Email